IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Adverse Drug Reaction: A Review

1Ms. Manisha Ankush Lavate, 2Mr. Sujit Trimbak Karape, 3Mr. Prathmesh Chandrakant Kshirsagar, 4Mr. Pravin Shahaji Shinde

1Student, 2Assistant professor , 3Student

1Dr.Babasaheb Ambedkar technical University, Lonare Raigad.,

2Dr.Babasaheb Ambedkar technical University, Lonare Raigad.,

3Dr.Babasaheb Ambedkar technical University, Lonare Raigad.

Abstract:

Adverse drug reactions (ADRs) are a major source of illness and mortality around the world. We highlight future goals for ADR research in this review, including discovering additional risk factors for ADRs, notably genetic and environmental variables. Advances in genetics and personalised medicine may aid in identifying individuals who are more likely to experience ADRs and tailoring pharmaceutical regimens accordingly. Creating biomarkers that can predict or detect ADRs could improve ADR detection and management. Large datasets can be analysed using machine learning and artificial intelligence to find patterns of ADRs and predict ADRs before they occur. Improved pharmacovigilance operations can aid in the detection and reporting of ADRs. Alternative therapies, such as herbal remedies and traditional medicines, can aid in the identification of probable ADRs and medication interactions. Involving patients in ADR research can aid in identifying patient viewpoints, preferences, and experiences with ADRs.

In conclusion, future ADR research should concentrate on identifying additional risk factors, establishing personalised medicine techniques, identifying biomarkers, using machine learning and AI, improving pharmacovigilance, studying alternative medicines, and integrating patients in research. These approaches have the potential to improve drug safety as well as patient outcomes.

Keywords: adverse drug reactions, ADRs, risk factors, early diagnosis, pharmacovigilance, detection, reporting, alternative therapies.

Introduction

What is the drug?

A drug is any chemical that is used to prevent, diagnose, treat, or relieve the symptoms of a disease or other abnormal condition.

The main premise underpinning medicine is that drugs interact with substances like proteins in the body and impact physiological activities.

An **adverse drug reaction** is any unpleasant consequence of medicine that occurs during clinical usage that is not expected to be therapeutic. An adverse drug event, on the other hand, is an unfavourable occurrence following drug exposure that is not always caused by the drug. Because only roughly 1500 people are expected to have been exposed to a medicine before it is marketed, little is known about its safety in clinical use. Because detection and diagnosis frequently rely on clinical acumen, medication safety assessment should be regarded as an inherent component of routine clinical practice. In this article, we will examine the current state of adverse medication responses, quickly discussing the complexities of the more unusual reactions and outlining a strategy to eradicate major adverse drug reactions. [1,2,3,4]

Definitions

The World Health Organization's (WHO) definition of an adverse drug reaction, which has been in use for about 30 years, is "a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for modification of physiological function"1. However, its usage of the word "noxious" (defined in the Oxford English Dictionary as "injurious, hurtful, harmful") is ambiguous; does it, for example, encompass all unfavourable reactions, regardless of how.....[5]

Importance of adverse drug reactions

ADRs are harmful and unanticipated side effects that occur when a person takes medication. Understanding the significance of ADRs is crucial in the realm of healthcare and medicine for several reasons, including:

1. **Patient Safety:** Adverse drug reactions can cause patient harm, which is why they must be identified, prevented, and managed. By reporting ADRs, healthcare workers can improve patient safety and lower the risk of medication damage.
2. **Drug Development:** Adverse event reports (ADRs) provide important information regarding a drug's safety and effectiveness. This data assists researchers and pharmaceutical companies in developing safer, more effective medications.
3. **Cost-Effectiveness:** ADRs can be expensive in terms of both healthcare costs and missed productivity. Healthcare practitioners can save healthcare expenses and improve overall healthcare outcomes by identifying and preventing ADRs.
4. **Legal and Regulatory Compliance:** ADRs must be reported by healthcare providers and pharmaceutical corporations by law. Failure to report ADRs can result in regulatory penalties as well as legal liabilities.

5. **Public Health:** ADRs are a major public health issue. Healthcare practitioners can reduce medication-related injury and enhance public health outcomes by identifying and managing ADRs.[6,7]

Types of ADR

Adverse Drug Reaction (ADR)

An ADR is described as "any noxious and unintended response to a drug that occurs at doses used in man for disease prevention, diagnosis, or therapy, or for the modification of physiological function."

Adverse drug reactions may be classified as -

- **Type A (Augmented reactions):**

Dose-related reactions (adverse effects at either a normal or high dose), such as serotonin syndrome or tricyclic anticholinergic effects

- **Type B (Bizzare):**

Non-dose-related reactions (i.e., any exposure is sufficient to cause such a reaction), such as allergic or anaphylactic reactions.

- **Type C (Chronic / Continuous reactions):**

Dose and time-related effects, such as adrenal suppression with corticosteroids or owing to dose accumulation.

- **Type D (Delayed reactions):**

Time-related responses are caused by extended use of a substance that does not accumulate (for example, tardive dyskinesia from antipsychotics).

- **Type E (End of treatment):**

Withdrawal reactions, or the unintended consequences of discontinuing the substance (for example, opiate withdrawal).

- **Type F (Failure of therapy):**

The unexpected failure of therapy occurs when a medicine's efficacy improves or decreases in an unfavourable way, such as decreased clearance of a drug by dialysis or decreased action of antibiotics due to resistance.[8,9,10,11]

Mechanism of Adverse drug reactions

Adverse drug reactions (ADRs) can occur due to several mechanisms, including:

1. **Pharmacological Mechanisms:** Adverse drug reactions can occur as a result of a medication's pharmacological effects. A drug, for example, may interact with another medication or a substance, resulting in a negative reaction. Alternatively, a medicine may have an unanticipated effect on the body, resulting in negative consequences.
2. **Immunological Mechanisms:** Adverse drug responses can also be caused by an immunological reaction to treatment. The immune system may see medicine as a foreign substance and mount an immunological reaction that has negative consequences. An allergic reaction is a type of reaction like this.
3. **Idiosyncratic Mechanisms:** Idiosyncratic adverse medication reactions are unpredictable and affect only a limited number of people. These reactions are not caused by a medication's pharmacological or immunological mechanisms, but rather by genetic, metabolic, or environmental variables.
4. **Dose-Related Mechanisms:** Adverse drug reactions can also arise as a result of medication dosage. Lower doses of medicine may have favourable effects, but higher amounts may be poisonous and result in negative outcomes.
5. **Withdrawal Mechanisms:** Adverse drug reactions can occur when a medicine is abruptly discontinued or when the dose is reduced too rapidly. This is referred to as a withdrawal reaction.[12,13,14,15]

Adverse drug reactions risk factor

Adverse drug reactions (ADRs) can happen to everyone who takes medication, but some people are more vulnerable than others. Here are some of the most common risk factors for ADRs:

1. **Age:** Because they may have many chronic diseases, take multiple drugs, and have diminished liver and kidney function, older persons are more likely to experience ADRs.
2. **Genetics:** Genes can alter how a person metabolises drugs, increasing the risk of ADRs. Some people, for example, may have genetic differences that predispose them to metabolise drugs more slowly, increasing the risk of toxicity.
3. **Renal or hepatic impairment:** Individuals with kidney or liver disease may have difficulties metabolising and excreting medicines, increasing the risk of toxicity.
4. **Polypharmacy:** Taking numerous drugs raises the risk of ADRs, especially if the medications interact or have overlapping adverse effects.
5. **Medical history:** People who have a history of ADRs or allergies to specific drugs are more likely to have similar responses in the future.
6. **Gender:** Some drugs may have differing effects on males and females, putting one gender at a higher risk of ADRs.
7. **Concurrent illnesses:** People who have specific medical problems, such as heart disease or diabetes, may be more susceptible to ADRs.

8. **Lifestyle factors:** Smoking, alcohol use, and poor nutrition can all alter how a drug is metabolised, increasing the risk of ADRs.[16,17,18,19,20,21]

Detection and reporting of Adverse drug reactions

How to recognize ADRs in patients

ADRs can be difficult, if not impossible, to separate from the condition being treated since they share physiological and pathological pathways.

However, the following method is useful in assessing potential drug-related ADRs:

1. Ensure that the medication requested is the medication received and taken by the patient at the recommended dose.
2. Take a comprehensive history and examine the patient
    - A full medicine and medical history should be taken
    - An ADR should always be your initial differential diagnostic
    - Determine whether this adverse reaction can be explained by any other cause, such as the patient's underlying disease, or other medications, including over-the-counter or traditional medicines, toxins, or foods.
    - It is critical that the patient be thoroughly researched in order to determine the true origin of any new medical concern.
    - A medication-related cause should be considered, especially if other causes do not explain the patient's state.
3. Identify time linkages by responding to the following question: Did the ADR occur shortly after the medication was administered? Some effects occur soon after the medication is administered, while others take time to manifest.
4. Perform a comprehensive physical examination, including any necessary laboratory tests:
    - Keep in mind that just a few medications cause unique physical symptoms.
    - Medicine eruptions, steroid-induced skin atrophy, and acute extrapyramidal reactions are examples of exceptions.
    - Laboratory testing is necessary if the medicine is thought to be crucial in enhancing patient care or if the results of the laboratory tests would improve patient management.
    - Describe the reaction as accurately as possible- Provide an accurate diagnosis where feasible
5. The impact of Dechallenge and Rechallenge should be assessed. • Dechallenge (removal of the suspected medication):
6. A positive dechallenge is the improvement or resolution of ADR after the suspected medicine is discontinued, indicating strong, but not conclusive, evidence of a medicine-produced reaction.
    - Rechallenge (reintroduction of the suspected medication after a dechallenge) Rechallenge is only justified when the benefit of reintroducing the suspected medicine to the patient outweighs the

risk of the reaction recurring, which is uncommon. In rare situations, repeated exposure may cause a more severe reaction. Rechallenge necessitates careful ethical judgement.

7. Examine the medicine's recognised pharmacology.

- Determine whether the reaction is known to occur with the specific suspected medicine, as described in the package insert or other reference.
- Keep in mind that just because a reaction isn't documented in the package insert doesn't imply it can't happen with that particular suspected medicine.

8. Report any suspected ADR to the hospital's ADR reporting person or immediately to the Jordan Pharmacovigilance Centre.

The seriousness of Adverse drug reactions

Any unfavourable medical development connected to the use of a medicinal product in a patient that, at any dose, results in one of the following is known as a serious adverse event or reaction.

1. Death Report if it is believed that the patient's demise was caused directly by the adverse response.

2. Life-Threatening Report if the patient was in grave danger of dying at the time of the adverse response or if it is thought that using the product or continuing to use it would cause the patient to pass away.

3. Hospitalisation (first or prolonged) Report if the suspected adverse response leads to hospital admission or a longer hospital stay.

4. Disability Report if the adverse reaction caused the patient to become significantly, persistently, or permanently disabled or unable (change, impairment, damage, or disruption in the patient's body function or structure, physical activities, or quality of life).

5. Congenital Anomaly Report if there is reason to believe that the use of a medicinal product either before or during pregnancy caused a negative outcome (birth defect) in the foetus.

6. Medically significant occurrence or response When determining whether other circumstances, such as significant medical occurrences that may not immediately pose a threat to life or result in hospitalisation or death but may put the patient in danger or necessitate intervention to avoid one of the other outcomes listed in the definition, medical and scientific judgement should be used above.[22,23,24,25,26]

Reporting of Adverse drug reactions

Adverse drug reactions (ADRs) can be reported in India by using the PvPI, or Pharmacovigilance Programme of India. The PvPI is a government-led programme with the goal of enhancing drug safety in India.

Here is a thorough procedure for reporting ADRs through the PvPI in India:

1**. Identify the ADR:** If you take a medicine and have an adverse reaction, note the medication and the symptoms you are feeling.

2. **Speak with a medical expert:** To report the ADR, speak with a medical expert such as a doctor or chemist. The information and instructions you need to report the ADR will be sent to you by them.

3. **Complete the ADR reporting form:** You can also report the ADR online by downloading and printing the ADR reporting form from the PvPI website and filling it out. You must fill out the form with information such as your name, address, medical history, and ADR details.
4. **Submit the ADR form:** Once the ADR form has been filled out, you may submit it online through the PvPI website's reporting system or by mail to the National Coordination Centre (NCC) for PvPI.

5. **Follow-up:** The NCC will analyse the ADR report and, if necessary, get in touch with you to follow up and get any additional information. They will also inform the drug's manufacturer and any pertinent regulatory bodies.
In conclusion, in order to report an adverse drug reaction (ADR) in India, one must first identify the ADR, then get in touch with a healthcare provider, complete the ADR form, send it in, and follow up with the NCC. To increase drug safety and stop further adverse drug reactions, reporting ADRs is crucial.[27,28,29,30,31]

Prevention and Management of Adverse Reactions

Adverse drug reactions (ADRs) can be avoided and managed by the use of many techniques, such as:
1. **Patient education:** Patients should be told what medications they are taking, including any possible side effects, and encouraged to report any negative side effects they encounter.
2. **Careful medication:** selection should be made by medical specialists, who should consider the patient's medical history, other drugs being used, and the possibility of drug interactions and side effects.
3. **Dose optimisation:** Based on the patient's age, weight, medical history, and renal or hepatic function, healthcare experts should recommend the right dose of medication.
4. **Monitoring:** Medical experts should periodically check patients for negative side effects, particularly when starting a new medicine or adjusting the dosage.
5. **Medication discontinuation:** If a patient has a serious or life-threatening ADR, the medication should be stopped right away.
6. **Treatment of ADRs:** Treatment of ADRs may entail stopping the medication, providing supportive care, or obtaining specialised care for the reaction's symptoms or side effects.
7. **Reporting ADRs:** To help uncover trends in ADRs and enhance drug safety, patients and healthcare providers should report ADRs to the appropriate regulatory authorities or through the Pharmacovigilance Programme of India (PvPI).
In conclusion, patient education, cautious medication selection and dose, monitoring, stopping the medication when necessary, treating ADRs, and reporting ADRs to improve drug safety are all necessary for preventing and managing ADRs.[32,33,34,35,36,37]

Adverse drug reactions (ADRs) should be the subject of future research because:

1**. Determining risk factors:** Additional research is required to pinpoint the genetic and environmental components that are specific risk factors for ADRs.

2. **Personalised medicine:** Genomic and personalised medicine advancements may make it possible to identify individuals who are more likely to experience adverse drug reactions and modify their treatment plans accordingly.

3. **Biomarkers:** The early diagnosis and management of ADRs may be enhanced by the development of biomarkers that can predict or detect ADRs.

4. **Machine learning and AI:** By analysing huge datasets, machine learning and artificial intelligence can find trends in ADRs and forecast them before they happen.

5. Pharmacovigilance: Increasing pharmacovigilance efforts may help in better ADR detection and reporting.

6**. Alternative therapy:** Research into conventional and herbal medicines, as well as alternative therapies, can assist spot possible adverse drug reactions (ADRs) and drug interactions.

7. **Patient involvement:** Getting patients involved in studies on ADRs can assist researchers understand the viewpoints, preferences, and experiences that patients have with ADRs.

In conclusion, future research on ADRs should concentrate on identifying additional risk factors, creating personalised medicine approaches, discovering biomarkers, utilising machine learning and AI, boosting pharmacovigilance, looking into alternative therapies, and involving patients in research.

Conclusion

Adverse drug reactions (ADRs) are a serious public health issue, and more study is required to better understand the underlying mechanisms, risk factors, and mitigation measures. The future of ADR research should centre on discovering new risk factors, creating personalised medicine strategies, discovering biomarkers, utilising machine learning and AI, enhancing pharmacovigilance activities, investigating alternative therapies, and involving patients in research. We can increase patient safety and ensure that drugs are used properly and effectively by better understanding ADRs.

Reference

1. Asscher AW, Parr GD, Whitmarsh VB. Towards the safer use of medicines. BMJ 1995;311:1003-5.
2. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 1995;29:41-9.
3. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-40.
4. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adv
5. RE Ferner *et al.* Errors in prescribing, preparing, and giving medicines—definition, classification, and prevention WHO. International drug monitoring: the role of national centres. Tech Rep Ser WHO 1972, no...
6. Bates DW, Spell N, Cuilen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-11.
7. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6
8. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991:18-45.
9. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Dibisceglie AM, Park Y, et al. Hepatic-failure and lactic-acidosis due to fialuridine (fiau), an investigational nucleoside analog for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
10. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi J-P, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incoroporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996;93:3592-7.
11. Atkin PA, Shenfield GM. Medication-related adverse reactions and the elderly: a literature review. Adverse Drug Reactions Toxicol Rev 1995;14:175-91
12. WHO: International drug monitoring: The role of the hospital; in WHO: Technical Report Series No. 425. Geneva, 1966.
13. Bonn D: Adverse drug reactions remain a major cause of death. Lancet 1998;351:1183.
14. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Jama 1998;279:1200–1205.
15. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK: Adverse drug reactions. BMJ 1998;316:1295–1298.
16. MooreNLecointreDNobletCMabilleMFrequency and cost of serious adverse drug reactions in a department of general medicineBr J Clin Pharmacol19984533013089517375

17. WesterKJönssonAKSpigsetODruidHHäggSIncidence of fatal adverse drug reactions: a population based studyBr J Clin Pharmacol200865457357918070216
18. LazarouJPomeranzBHCoreyPNIncidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studiesJAMA199827915120012059555760
19. WhiteTJArakelianARhoJPCounting the costs of drug-related adverse eventsPharmacoeconomics199915544545810537962
20. TangiisuranBGozzoliMPDaviesJGRajkumarCAdverse drug reactions in older peopleReviews in Clinical Gerontology20102003246259
21. PatelKJKediaMSBajpaiDMehtaSSKshirsagarNAGogtayNJEvaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective studyBMC Clin Pharmacol20077817662147
22. Safety of Medicines, A guide to detecting and reporting adverse drug reactions. World Health Organization (WHO) Geneva 2002.
23. Safety Monitoring of Medicinal Products, Guidelines for setting up and running a Pharmacovigilance Centre. the Uppsala Monitoring Centre (the UMC), WHO Collaborating Centre for International Drug Monitoring, 2000.
24. VOLUME 9A -of The Rules Governing Medicinal Products in the European Union– Guidelines on Pharmacovigilance for Medicinal Products for Human Use, (EMEA) 2008
25. ICH Topic E2E Pharmacovigilance Planning (Pvp), European Medicines Agency, June 2005
26. ICH Topic E2D, Definitions and standards for expedited reporting, November 2003
27. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). March 2005.
28. Pharmacovigilance guidance for countries participating in AMFm phase 1, WHO-MMV joint technical consultation on active pharmacovigilance monitoring with a special focus on AMFm, WHO April 2009
29. Procedure for the SFDA on the undertaking of Pharmacovigilance activities, Saudi Food and Drug Authority.
30. Guidelines for detecting and reporting adverse drug reactions (Egyptian Pharmacovigilance Center), 2010
31. Pharmacovigilance guideline for adverse drug reaction (JFDA), 2010
32. Manger WM. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 2006; 1073: 1-20
33. Bergland BE. Pheochromocytoma presenting as shock. Am J Emerg Med 1989; 7: 44-8 I
34. Imperadore F, Azzolini M, Piscioli F, et al. A rare cause of cardiogenic shock: catecholamine cardiomyopathy of phe- ochromocytoma. Ital Heart J 2002; 3: 375-8
35. Mohamed HA, Aldakar MO, Habib N. Cardiogenic shock due to acute hemorrhagic necrosis of a pheochromocytoma: a case report and review of the literature. Can J Cardiol 2003; 19: 573-6

36. De Wilde D. Velkeniers B, Huyghens L, et al. The paradox of hypotension and pheochromocytoma: a case report. Eur J Emerg Med 2004; 11: 237-9

37. Lund-Johansen P. Shock after administration of phenothiazines in patients with pheochromocytoma. Acta Med Scand 1962; 172: 525-9